GlassScriptPhysician profile
Timothy M Patterson
NPI 1902132871
$5,727.61
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $841 · 2021: $872 · 2022: $904 · 2023: $1,758 · 2024: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,164.85 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $465.52 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Pfizer INC. | $441.40 | 2019-2024 | |
| Abbvie INC. | $425.85 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.32 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $262.30 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $247.03 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $233.92 | 2020-2022 | |
| Glaxosmithkline, LLC. | $189.66 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $177.42 | 2019-2023 | Belsomra, Steglatro |
| Amarin Pharma, INC. | $152.70 | 2019-2021 | |
| Exact Sciences Corporation | $152.05 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.32 | 2020-2024 | Xifaxan |
| Astellas Pharma US INC | $130.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.53 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.